Demographic characteristics
| . | GM-CSF + Epoetin Alfa . | GM-CSF + Placebo . | Total . |
|---|---|---|---|
| Male | 34 | 12 | 46 |
| Female | 11 | 9 | 20 |
| White | 44 | 20 | 64 |
| Black | 1 | 1 | 2 |
| Mean age (y) (±SD) | 62.4 (±14.9) | 62.9 (±14.2) | 62.5 (±14.6) |
| Age range (y) | 21-95 | 25-84 | 21-95 |
| FAB classification | |||
| RA | 13 | 7 | 20 |
| RAEB | 25 | 10 | 35 |
| RARS | 6 | 3 | 9 |
| RAEB-t | 1 | 1 | 2 |
| . | GM-CSF + Epoetin Alfa . | GM-CSF + Placebo . | Total . |
|---|---|---|---|
| Male | 34 | 12 | 46 |
| Female | 11 | 9 | 20 |
| White | 44 | 20 | 64 |
| Black | 1 | 1 | 2 |
| Mean age (y) (±SD) | 62.4 (±14.9) | 62.9 (±14.2) | 62.5 (±14.6) |
| Age range (y) | 21-95 | 25-84 | 21-95 |
| FAB classification | |||
| RA | 13 | 7 | 20 |
| RAEB | 25 | 10 | 35 |
| RARS | 6 | 3 | 9 |
| RAEB-t | 1 | 1 | 2 |
FAB, French-American-British group; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RAEB-t, refractory anemia with excess blasts in transformation.